GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
The investment will accelerate the overall Sarclisa development program
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Tislelizumab is now approved for seven indications in China
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The interim data combines three mRNAs into one therapy injected directly into the tumour
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
